Recursion Pharmaceuticals vs Viridian Therapeutics, Inc.\de
Recursion Pharmaceuticals and Viridian Therapeutics, Inc.\de are similar in size: $74.7m and $70.8m of revenue in their latest fiscal years. Viridian Therapeutics, Inc.\de grew faster (23359.9% against 26.9%). Viridian Therapeutics, Inc.\de kept more of each dollar of sales as profit: a net margin of -483.6% against -863.4%. Recursion Pharmaceuticals carries less debt relative to equity (1.6% against 6.9%).
| Latest fiscal year | Recursion PharmaceuticalsRXRX, 2025 | Viridian Therapeutics, Inc.\deVRDN, 2025 |
|---|---|---|
| Revenue | $74.7m | $70.8m |
| Revenue growth | 26.9% | 23359.9% |
| Net income | −$645m | −$343m |
| Operating margin | -867.9% | -512.9% |
| Net margin | -863.4% | -483.6% |
| Return on equity | -59.5% | -49.2% |
| Free cash flow | −$378m | −$277m |
| Cash | $743m | $212m |
| Total debt | $18.7m | $49.9m |
| Debt to equity | 1.6% | 6.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 252 |
| Market value | $2.15bn | $2.86bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 35 sales | 1 buys, 3 sales |